PCRonline @ ESC Congress 2025: the interventional cardiology perspective!

Condensed take-home messages from ESC Congress 2025

Stay updated with the latest in interventional cardiology at #ESCCongress 2025!

Mirvat Alasnag, Elad Asher, Aaysha Cader, Ali Nazmi Calik, Jonathan Curio, Chiara De Biase, Daniele Giacoppo, Kalaivani Mahadevan, Yohei Ohno, Nicola Ryan and Alex Sticchi share their take on a selection of key Hotline Sessions, Guidelines and Late-Breaking Trials of interest to interventional cardiologists during ESC Congress 2025, including exclusive interviews with principal investigators.

DOUBLE-CHOICE: Anesthesia strategies and self-expanding valve types for TAVI - An interview with Mohamed Abdel-Wahab
The AQUATIC trial: Assessment of quitting vs. using aspirin therapy in patients with stabilized CAD after stenting who require long-term oral anticoagulation
The DUAL-ACS Trial: Duration of DAPT in ACS - An interview with David Newby
OPTION-STEMI: Timing of complete revascularization during index hospitalization in patients with STEMI and multivessel disease
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
TAILORED-CHIP: Tailored Antiplatelet Therapy for Complex High-Risk PCI
TARGET-FIRST: Early aspirin discontinuation after PCI in acute MI patients
DAPT-SHOCK-AMI trial: Cangrelor in cardiogenic shock
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
The TOP-CABG trial: Timing of platelet inhibition after coronary artery bypass grafting
OPINION Trial: Surgical left atrial appendage occlusion in VHD without AF

This independent ESC Congress 2025 coverage is available thanks to the unrestricted support of Edwards Lifesciences